Table 4. Comparison of Clinical features in CAP patients between two MLVA groups.

	Group 1a	Group 2b	p value
Patients number (n)	49	87
Gender male, n (%)	24 (49.0, 35.0–63.0)	37 (42.5, 32.1–52.9)	0.479
Age (years)	35.6±14.6	29.3±11.5	0.006
Comorbidities, n (%)	4 (8.2, 0.5–15.9)	3 (3.4, −0.4–7.2)	0.429
Smoking, n (%)	9 (18.4, 7.6–29.2)	12 (13.8, 6.6–21.0)	0.622
Fever, n (%)	46 (93.9, 87.2–100.6)	84 (96.6, 92.8–100.4)	0.68
Tmax (°C)	39.1±0.7	39.2±0.7	0.719
Cough, n (%)	49 (100.0, 100.0–100.0)	84 (96.6, 92.8–100.4)	0.303
Sputum, n (%)	37 (75.5, 63.5–87.5)	67 (77.0, 68.2–85.8)	1.000
WBC (×109/L)	7.6±2.3	7.6±2.6	0.892
PSI score	39.3±17.7	28.5±13.8	<0.001
Total duration of fever (days)	5.8±3.7	5.2±3.0	0.288
Total duration of cough (days)	17.8 (10.0)	13.6 (7.0)	0.011
Length of hospitalization (days)	6 (14)	6 (10)	0.472

Note: The data are presented as n (%, 95% confidence intervals), mean ± SD or median (IQR).

^a Group 1: patients infected with MLVA types “J & U”;

^b Group 2: patients infected with other MLVA types.